Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02908880 · ClinicalTrials.gov registry record · NA

MANTA Percutaneous Vascular Closure Device - The SAFE MANTA Study

A NA study of Femoral Arteriotomy Closure, sponsored by Essential Medical.

Completed
Registry status
NA
Development phase
263
Enrollment target
19
Study locations

NCT02908880 is a NA study of Femoral Arteriotomy Closure that has completed, run by Essential Medical. The registered enrollment target is 263 participants. The trial reports 19 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02908880, a NA study of Femoral Arteriotomy Closure, has completed, sponsored by Essential Medical.

COMPLETED
Registry status
NA
Development phase
263 participants
Enrollment target
19
Study locations

Study Summary

Research study which tests the safety and effectiveness of a new vascular closure device to close the femoral access puncture that is created in patients who require this form of access in order to perform the planned procedure. The MANTA device is expected to seal the femoral access puncture in less than 1 minute. This may result in less blood loss and a shorter time to walking compared to alternative closure means. Use of the MANTA device in this study is experimental. All other parts of the procedure involve standard medical care.

Interventions

  • DEVICE MANTA vascular closure device

Study Locations (19)

Pennsylvania

  • Hershey Medical Center - Hershey
  • Temple University Hospital - Philadelphia
  • Lankenau Heart Group - Wynnewood

Texas

  • Houston Methodist - Houston
  • St. Luke's Hospital - Texas Heart - Houston
  • The Heart Hospital Baylor Plano - Plano

California

  • San Diego VA Medical Center - San Diego

District of Columbia

  • Washington Hospital Center - Washington D.C.

Illinois

  • Evanston Hospital - Evanston

Indiana

  • St. Vincent Heart Center - Indianapolis

Michigan

  • Henry Ford - Detroit

Missouri

  • St. Luke Hospital (Mid America Heart) - Kansas City

Trial Details

FieldValue
Enrollment Target 263 participants
Start Date 2016-12
Est. Completion 2017-12
Phase NA

Sponsor

Essential Medical

3 total trials

What the Registry Record Tells You About NCT02908880

The ClinicalTrials.gov registry entry for NCT02908880 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Essential Medical, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Femoral Arteriotomy Closure appearing as the primary indexed condition, and to 1 intervention - of which MANTA vascular closure device is the first listed.

NCT02908880 reports 19 study locations spanning 15 distinct geographic areas - top geographies include Pennsylvania, Texas, California.

Frequently Asked Questions

What is clinical trial NCT02908880 about?

NCT02908880 is a clinical study titled "MANTA Percutaneous Vascular Closure Device - The SAFE MANTA Study". Research study which tests the safety and effectiveness of a new vascular closure device to close the femoral access puncture that is created in patients who require this form of access in order to perform the planned procedure. The MANTA device is expected to seal the femoral access puncture in les...

What is the current status of trial NCT02908880?

This trial is currently completed. It is a NA study. The enrollment target is 263 participants. The study started on 2016-12. Estimated completion is 2017-12.

What conditions does trial NCT02908880 study?

This clinical trial studies the following conditions: Femoral Arteriotomy Closure.

What interventions are being tested in trial NCT02908880?

The interventions under investigation include: MANTA vascular closure device (DEVICE).

Who is sponsoring clinical trial NCT02908880?

This trial is sponsored by Essential Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02908880 being conducted?

This trial has 19 study locations across California, District of Columbia, Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.